| Name | Title | Contact Details |
|---|---|---|
Marc Bellisario |
Sr. Director, R&D Program Management | Profile |
Michael Saporito |
Vice President of Research and Preclinical Development | Profile |
Michael Barr |
Sr Director Human Resources - Marinus Pharmaceutical | Profile |
Steven Pfanstiel |
Chief Financial Officer | Profile |
Scott Braunstein |
Chief Executive Officer | Profile |
Talia Technology (Marco Ophthalmic Inc.) is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials.
ZEST Dental Solutions has been manufacturing overdenture implant attachment systems as a global leader and being one of the top dental implant manufacturers for over forty years.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies. We market our products in more than 165 countries and territories, and every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world. Mylans mission is grounded in our belief that every person matters and should have the opportunity to live the healthiest life possible. We have built our business model consistent with this belief, and through it, we are impacting people around the world with each passing year. Providing universal access to medicine is the core purpose of our model. To provide access, we must be able to satisfy the needs of an incredibly diversified global marketplace whose economic and political systems, approaches to delivering and paying for healthcare, languages and traditions, and customer and patient requirements vary by location and over time.